Get the Stockscreener App
241.95
3.25%
-8.13
After Hours:
267.00
25.05
+10.35%
Bio Rad Laboratories Inc stock is traded at $241.95, with a volume of 430.85K.
It is down -3.25% in the last 24 hours and up +0.26% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$250.08
Open:
$247.19
24h Volume:
430.85K
Relative Volume:
1.25
Market Cap:
$5.36B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-8.8529
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
-7.67%
1M Performance:
+0.26%
6M Performance:
-32.96%
1Y Performance:
-28.49%
1-Day Range:
$241.02
$251.34
1-Week Range:
$241.02
$267.49
52-Week Range:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
241.95 | 6.81B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Navigating Contradictions: Insights from Bio-Rad's Q2 2025 Earnings Call on Process Chromatography and Market Dynamics - AInvest
Bio-Rad Laboratories, Inc. 2025 Q2ResultsEarnings Call Presentation (NYSE:BIO) - Seeking Alpha
Earnings call transcript: Bio-Rad Labs beats Q2 2025 forecasts, shares dip - Investing.com
Bio-Rad Laboratories shares rise 12.47% after-hours after Q2 earnings beat estimates and acquisition of Stilla Technologies. - AInvest
Bio-Rad: Q2 Earnings Snapshot - The Washington Post
Bio Rad Laboratories Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Bio-Rad Reports Q2 2025 Financial Results - TipRanks
Bio-Rad Labs soars after significant earnings beat By Investing.com - Investing.com Canada
Bio-Rad Reports Second-Quarter 2025 Financial Results - Yahoo Finance
Hematology Analyzer Market Generated Opportunities, Future - openPR.com
Future Scope of Host Cell Protein Impurity Characterization - openPR.com
Can Bio Rad Laboratories Inc. recover in the next quarterHigh Win Rate Trading Opportunities Detected - metal.it
Why is Bio Rad Laboratories Inc. stock attracting strong analyst attentionAI Powered Entry Points That Work - jammulinksnews.com
Bio-Rad Laboratories, Inc. Q2 2025 Earnings Preview - MSN
Minimal Residual Disease Testing Market is evolving rapidly - openPR.com
Blood Processing Devices and Consumables Market Set to Witness - openPR.com
Drug Abuse Testing Market Forecast and Company Analysis - GlobeNewswire
Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic - Yahoo Finance
New Product Launches: Will They Boost Bio Rad Laboratories Inc. Stock in 2025 - metal.it
Bio-Rad Laboratories Appoints New Executive VP for Growth - The Globe and Mail
Epigenetics Market Set to Surpass USD 2.79 Billion by 2032 | Key - openPR.com
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - GlobeNewswire Inc.
Human Papilloma Virus Testing Market Research Report - GlobeNewswire
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche - Yahoo Finance
Nucleic Acid Isolation and Purification Market Outlook 2025 - openPR.com
Loop-Mediated Isothermal Amplification (LAMP) Market Outlook - openPR.com
Bio-Rad Laboratories A BIO 2025Q2 Earnings Preview Downside Ahead on Weak Demand for Clinical Diagnostics - AInvest
Bio-Rad Laboratories B BIO.B 2025Q2 Earnings Preview Downside Risk as Operating Income Declines - AInvest
Published on: 2025-07-29 03:10:13 - metal.it
Does Bio Rad Laboratories Inc. stock perform well during market downturnsValue Investing Recommendation For Every Investor - jammulinksnews.com
What are Bio Rad Laboratories Inc. company’s key revenue driversPost Market Outlook For Every Investor - jammulinksnews.com
Bio-Rad appoints Rajat Mehta as new EVP of global commercial operations - Investing.com Nigeria
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations - The Globe and Mail
How high can Bio Rad Laboratories Inc. stock price go in 2025Smart Allocation Stock Pick Insights Gaining Interest - beatles.ru
What are the technical indicators suggesting about Bio Rad Laboratories Inc.Stock Strategy Trend Scanner To Watch Now - jammulinksnews.com
Is Bio Rad Laboratories Inc. a growth stock or a value stockConsistent double returns - jammulinksnews.com
What makes Bio Rad Laboratories Inc. stock price move sharplyAchieve breakthrough investment performance - jammulinksnews.com
When is Bio Rad Laboratories Inc. stock expected to show significant growthBuild a portfolio that stands the test of time - jammulinksnews.com
NGS Sample Preparation Market Set to Witness Significant Growth - openPR.com
Is Bio Rad Laboratories Inc. stock overvalued or undervaluedGet timely alerts on market opportunities - jammulinksnews.com
How does Bio Rad Laboratories Inc. generate profit in a changing economyMaximize returns with expert trading insights - jammulinksnews.com
How strong is Bio Rad Laboratories Inc. company’s balance sheetDiscover market opportunities with real-time data - jammulinksnews.com
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):